By improving insulin sensitivity and reducing chronic inflammation, it may help preserve muscle mass and function in individuals at risk of sarcopenia, however, the study revealed that metformin does not improve physical performance in older adults with probable sarcopenia and frailty, thus, alternative interventions for maintaining mobility and function in this vulnerable population need to be explored [125]
Thats usually how this shows up
Any early weight changes may be attributed to: Reduced caloric intake due to appetite suppression Decreased fluid retention in some individuals Changes in glycogen stores and associated water weight Reduced food volume in the digestive system It is important to understand that week one weight changes are not indicative of long-term results
As patients lose weight on GLP-1 therapy, increased mobility often becomes feasible, creating opportunities for enhanced physical activity that further supports weight management and joint function
Melanoma is the most dangerous type of skin cancer
That gap leaves a lot of patients paying full retail price